Elevance Health (ELV) exceeded analysts’ expectations in its second-quarter earnings report, driven by strong performance in CarelonRx and investment income. However, the company’s medical membership declined, and premium revenues fell. Despite the positive earnings, analysts have lowered their estimates for the stock, raising concerns about its future performance.